Invalidity Enablement

Federal Circuit Upholds Patent Invalidity for Lack of Enablement Due to Absence of Actual Dosage Disclosure

In a series of recent rulings, the Federal Circuit affirmed key patent decisions, notably invalidating Wyeth’s patents on irreversible EGFR inhibitors for non-small cell lung cancer due to lack of enablement. The court found that the patent specifications failed to disclose actual therapeutic dosages, leaving undue ex…